{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:04:38Z","timestamp":1790690678216,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000782","name":"European Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["KiKa-236"],"award-info":[{"award-number":["KiKa-236"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KW-11863"],"award-info":[{"award-number":["KW-11863"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023479","name":"CRIS Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003761","name":"Universitair Medisch Centrum Utrecht","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100230","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:24:37Z","timestamp":1775730277000},"page":"100230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-6762","authenticated-orcid":false,"given":"Tamara C. A. I.","family":"Verbeek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-272X","authenticated-orcid":false,"given":"Kirsten S.","family":"Vrenken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan T. C. J. M.","family":"Arentsen-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"van den Hoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4986-1656","authenticated-orcid":false,"given":"Ronald W.","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.bneo.2026.100230_bib1","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1200\/JCO.23.01286","article-title":"Advancing diagnostics and therapy to reach universal cure in childhood ALL","volume":"41","author":"Pieters","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100230_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2026.100230_bib3","doi-asserted-by":"crossref","first-page":"100204","DOI":"10.1016\/j.ejcped.2024.100204","article-title":"KMT2A-rearranged acute lymphoblastic leukaemia","volume":"4","author":"Kotecha RS","year":"2024","journal-title":"EJC Paediatric Oncology"},{"issue":"9","key":"10.1016\/j.bneo.2026.100230_bib4","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3324\/haematol.2024.285642","article-title":"KMT2A-rearranged acute lymphoblastic leukemia in infants: current progress and challenges","volume":"110","author":"Stutterheim","year":"2025","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bneo.2026.100230_bib5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/leu.2011.278","article-title":"Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia","volume":"26","author":"Stumpel","year":"2012","journal-title":"Leukemia"},{"issue":"9583","key":"10.1016\/j.bneo.2026.100230_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.bneo.2026.100230_bib7","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bneo.2026.100230_bib8","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2026.100230_bib9","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/cncr.34667","article-title":"Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"129","author":"Queudeville","year":"2023","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bneo.2026.100230_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/08880018.2022.2049936","article-title":"Outcomes of blinatumomab based therapy in children with relapsed, persistent, or refractory acute lymphoblastic leukemia: a multicenter study focusing on predictors of response and post-treatment immunoglobulin production","volume":"39","author":"Essa","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100230_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41408-023-00924-5","article-title":"Late effects in survivors of infant acute lymphoblastic leukaemia-a study of the Australian and New Zealand Children's Haematology\/Oncology Group","volume":"13","author":"Mironova","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.bneo.2026.100230_bib12","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1038\/bcj.2016.129","article-title":"Late effects in survivors of infantile acute leukemia: a study of the L.E.A program","volume":"7","author":"Gandemer","year":"2017","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.bneo.2026.100230_bib13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.20.02333","article-title":"Clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukemia treated on the interfant-06 protocol","volume":"39","author":"Stutterheim","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100230_bib14","doi-asserted-by":"crossref","first-page":"E170","DOI":"10.1073\/pnas.1210419110","article-title":"Defining principles of combination drug mechanisms of action","volume":"110","author":"Pritchard","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bneo.2026.100230_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"2","key":"10.1016\/j.bneo.2026.100230_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2023.12.001","article-title":"Ex vivo discovery of synergistic drug combinations for hematologic malignancies","volume":"29","author":"Ali","year":"2024","journal-title":"SLAS Discov"},{"issue":"4","key":"10.1016\/j.bneo.2026.100230_bib17","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.3324\/haematol.2017.174060","article-title":"Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo","volume":"103","author":"Kerstjens","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2026.100230_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41375-024-02400-w","article-title":"Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines","volume":"39","author":"Safa-Tahar-Henni","year":"2025","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2026.100230_bib19","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.V76.11.2327.2327","article-title":"In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions","volume":"76","author":"Pieters","year":"1990","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2026.100230_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237096","article-title":"RandoMice, a novel, user-friendly randomization tool in animal research","volume":"15","author":"van Eenige","year":"2020","journal-title":"PLoS One"},{"issue":"W1","key":"10.1016\/j.bneo.2026.100230_bib21","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.bneo.2026.100230_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/leu.2017.216","article-title":"The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20\/RNF40\/WAC-H2B ubiquitination axis","volume":"32","author":"Garrido Castro","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2026.100230_bib23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41375-021-01177-6","article-title":"FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631","volume":"35","author":"Brown","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2026.100230_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/emmm.201201703","article-title":"Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations","volume":"5","author":"Rehe","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"7","key":"10.1016\/j.bneo.2026.100230_bib25","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2010-11-320309","article-title":"Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment","volume":"118","author":"Schmitz","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100230_bib26","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s42003-024-06916-w","article-title":"Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia","volume":"7","author":"Verbeek","year":"2024","journal-title":"Commun Biol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100230_bib27","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2004-09-3667","article-title":"Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia","volume":"106","author":"Stam","year":"2005","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bneo.2026.100230_bib28","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2003.11.031","article-title":"Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia","volume":"21","author":"Den Boer","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100230_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41375-022-01746-3","article-title":"Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy","volume":"37","author":"Cheung","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2026.100230_bib30","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/biomedicines10030638","article-title":"High-throughput drug library screening in primary","volume":"10","author":"Wander","year":"2022","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.bneo.2026.100230_bib31","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100230_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0145-2126(94)00126-U","article-title":"Drug combination testing in acute lymphoblastic leukemia using the MTT assay","volume":"19","author":"Kaspers","year":"1995","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.bneo.2026.100230_bib33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2016.79","article-title":"Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia","volume":"30","author":"Pal","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2026.100230_bib34","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2026.100230_bib35","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.4731","article-title":"Ex vivo drug sensitivity imaging-based platform for primary acute lymphoblastic leukemia cells","volume":"13","author":"Rowland","year":"2023","journal-title":"Bio Protoc"},{"issue":"4","key":"10.1016\/j.bneo.2026.100230_bib36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.bneo.2026.100230_bib37","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2018.206375","article-title":"Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis","volume":"104","author":"Agraz-Doblas","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bneo.2026.100230_bib38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2125.2011.03925.x","article-title":"Understanding the time course of pharmacological effect: a PKPD approach","volume":"71","author":"Wright","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100230_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cts.12448","article-title":"Importance of drug pharmacokinetics at the site of action","volume":"10","author":"Rizk","year":"2017","journal-title":"Clin Transl Sci"},{"issue":"3","key":"10.1016\/j.bneo.2026.100230_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/jpet.121.000584","article-title":"A novel integrated pharmacokinetic-pharmacodynamic model to evaluate combination therapy and determine in vivo synergism","volume":"377","author":"Choi","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.bneo.2026.100230_bib41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2005-07-3011","article-title":"Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group","volume":"108","author":"Hilden","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100230_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-017-0380-3","article-title":"New therapeutic strategies in acute lymphocytic leukemia","volume":"12","author":"Man","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"7954","key":"10.1016\/j.bneo.2026.100230_bib43","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bneo.2026.100230_bib44","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.3390\/ijms25116020","article-title":"Distinct responses to menin inhibition and synergy with DOT1L inhibition in","volume":"25","author":"Adriaanse","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:16:10Z","timestamp":1790687770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000415"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100230","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100230"}}